-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The availability of L-arginine in tumors is a key determinant of highly effective anti-tumor T cell responses
.
L-arginine in tumor cells is generally at a low concentration.
Increasing the concentration of L-arginine in the tumor may greatly enhance the anti-tumor response of immune checkpoint inhibitors.
Recently, researchers have studied whether L-arginine can have a synergistic effect with PD-L1 blockade
.
In mice with subcutaneous MC38 tumors, the researchers conducted tests and found that daily oral L-arginine and anti-PD-L1 treatment have a synergistic effect and increase the survival rate of the mice
L-arginine and PD-L1 blocking therapies work synergistically to limit tumor growth in mice.
L-Arg bacteria work synergistically with PD-L1 inhibitors to promote the rejection of MC38 tumors
.
.
L-Arg bacteria work synergistically with PD-L1 inhibitors to promote the rejection of MC38 tumors
The strain can be colonized in tumors and continuously convert the metabolic waste products accumulated in tumors, ammonia, into L-arginine.
In summary, these results indicate that engineered microbial therapy can metabolize the tumor microenvironment, thereby improving the efficacy of immunotherapy
Original source:
Original source:Fernando P.
Fernando P.
Leave a message here
